

Andrea Cavazzoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4192391/publications.pdf>

Version: 2024-02-01

70
papers

2,347
citations

126907

33
h-index

223800

46
g-index

71
all docs

71
docs citations

71
times ranked

3830
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. <i>Neoplasia</i> , 2017, 19, 637-648.	5.3	81
2	Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis. <i>Journal of Physiology</i> , 2002, 540, 499-508.	2.9	79
3	Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. <i>Cancer Letters</i> , 2012, 323, 77-87.	7.2	78
4	5-Benzylidene-hydantoin s as new EGFR inhibitors with antiproliferative activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4021-4025.	2.2	75
5	Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. <i>Tumor Biology</i> , 2017, 39, 101042831769502.	1.8	73
6	Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. <i>Biochemical Pharmacology</i> , 2009, 78, 460-468.	4.4	71
7	Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 174.	8.6	70
8	The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 72.	8.6	68
9	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5873-5884.	3.0	67
10	Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK/mTORC1 signaling. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 67-78.	2.5	65
11	Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 361-370.	4.1	63
12	Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells. <i>Scientific Reports</i> , 2019, 9, 13014.	3.3	62
13	PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition. <i>Cancers</i> , 2019, 11, 1318.	3.7	61
14	Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR- Activating Mutation. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1051-1063.	1.1	58
15	Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands. <i>European Journal of Medicinal Chemistry</i> , 2017, 128, 140-153.	5.5	58
16	Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress. <i>Journal of Physiology</i> , 2006, 576, 391-401.	2.9	57
17	Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. <i>Molecular Cancer</i> , 2014, 13, 143.	19.2	55
18	FGFR as potential target in the treatment of squamous non small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 527-539.	7.7	55

#	ARTICLE	IF	CITATIONS
19	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 2541-2548.	3.0	54
20	Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 2251-2264.	6.4	53
21	Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines. <i>PLoS ONE</i> , 2015, 10, e0141795.	2.5	51
22	Osmotic Regulation of ATA2 mRNA Expression and Amino Acid Transport System A Activity. <i>Biochemical and Biophysical Research Communications</i> , 2001, 283, 174-178.	2.1	49
23	Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2038-2050.	6.4	49
24	Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 222.	8.6	45
25	Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring <i>PIK3CA</i> Gene Alterations. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1916-1927.	4.1	43
26	Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification. <i>PLoS ONE</i> , 2013, 8, e78656.	2.5	39
27	5-Benzylidene-hydantoins: Synthesis and antiproliferative activity on A549 lung cancer cell line. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 3471-3479.	5.5	38
28	Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion. <i>Mini-Reviews in Medicinal Chemistry</i> , 2011, 11, 1019-1030.	2.4	37
29	MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report. <i>Translational Oncology</i> , 2019, 12, 116-121.	3.7	37
30	Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line. <i>Oncogene</i> , 2004, 23, 8439-8446.	5.9	36
31	Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines. <i>Molecular Cancer</i> , 2011, 10, 143.	19.2	36
32	Synergistic activity of letrozole and sorafenib on breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 79-88.	2.5	35
33	Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines. <i>Molecular Cancer</i> , 2012, 11, 91.	19.2	35
34	Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion. <i>Targeted Oncology</i> , 2019, 14, 619-626.	3.6	33
35	Induction of BGT-1 and amino acid System A transport activities in endothelial cells exposed to hyperosmolarity. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2000, 279, R1580-R1589.	1.8	32
36	Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1104-1111.	1.1	32

#	ARTICLE	IF	CITATIONS
37	Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines. <i>Biochemical Pharmacology</i> , 2010, 80, 179-187.	4.4	31
38	Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib. <i>Cancers</i> , 2021, 13, 6.	3.7	30
39	Intrapleural polymeric films containing cisplatin for malignant pleural mesothelioma in a rat tumour model: a preliminary study. <i>European Journal of Cardio-thoracic Surgery</i> , 2010, 37, 557-565.	1.4	28
40	Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. <i>Oncotarget</i> , 2017, 8, 91841-91859.	1.8	28
41	Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 299-307.	2.3	27
42	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. <i>Current Pharmaceutical Design</i> , 2013, 19, 818-832.	1.9	24
43	Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 666.	3.7	24
44	New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway. <i>Frontiers in Oncology</i> , 2017, 7, 170.	2.8	21
45	Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5165.	4.1	21
46	Roles of compatible osmolytes and heat shock protein 70 in the induction of tolerance to stresses in porcine endothelial cells. <i>Journal of Physiology</i> , 2004, 555, 757-767.	2.9	20
47	Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. <i>Oncotarget</i> , 2017, 8, 53068-53083.	1.8	19
48	Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines. <i>Frontiers in Oncology</i> , 2020, 10, 563249.	2.8	18
49	Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line. <i>Cancer Letters</i> , 2007, 246, 69-81.	7.2	17
50	Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer. <i>Neoplasia</i> , 2013, 15, 61-118.	5.3	13
51	Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma. <i>Journal of Thoracic Disease</i> , 2018, 10, S194-S206.	1.4	12
52	Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. <i>Current Pharmaceutical Design</i> , 2013, 19, 818-32.	1.9	12
53	Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method. <i>PLoS ONE</i> , 2015, 10, e0142891.	2.5	11
54	Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model. <i>Journal of Thoracic Disease</i> , 2018, 10, S207-S220.	1.4	11

#	ARTICLE	IF	CITATIONS
55	Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR. <i>European Journal of Medicinal Chemistry</i> , 2019, 162, 507-524.	5.5	11
56	Hypertonic Stress and Amino Acid Deprivation Both Increase Expression of mRNA for Amino Acid Transport System A. <i>Journal of General Physiology</i> , 2005, 125, 37-39.	1.9	10
57	New Imidazo[2,1- <i>b</i>][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma. <i>Anticancer Research</i> , 2020, 40, 4913-4919.	1.1	9
58	Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. <i>Life</i> , 2021, 11, 843.	2.4	5
59	TRAIL-induced apoptosis of FHIT-negative lung cancer cells is inhibited by FHIT expression. <i>Journal of Cellular Physiology</i> , 2009, 220, 492-498.	4.1	3
60	Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5290-5294.	2.2	3
61	YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100278.	1.1	3
62	Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies. , 2019, , 25-60.		2
63	347 Evaluation of Gefitinib Maintenance in an EGFR-mutant NSCL Cell Line With Acquired Resistance. <i>European Journal of Cancer</i> , 2012, 48, S84-S85.	2.8	1
64	Isolation of circulating lung tumour cells using a non-EpCAM-based capture method. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2012, 8, 116-117.	0.4	1
65	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. <i>Current Pharmaceutical Design</i> , 2012, 19, 818-832.	1.9	1
66	It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer. <i>Life</i> , 2022, 12, 960.	2.4	1
67	1019 Erlotinib Potentiates Cetuximab-dependent Cell Cytotoxicity in Egfr Wild Type Nsclc Cell Lines. <i>European Journal of Cancer</i> , 2012, 48, S246.	2.8	0
68	404 Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung. <i>European Journal of Cancer</i> , 2014, 50, 129.	2.8	0
69	692: Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations. <i>European Journal of Cancer</i> , 2014, 50, S166-S167.	2.8	0
70	Abstract 3011: Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models. , 2021, , .		0